EU may expand Tresiba indication

Share this article:

The EU's Committee for Medicinal Products for Human Use is endorsing expanded indications for Novo Nordisk's Type 2 diabetes medications Tresiba and Victoza.

The company said in a statement that if the European Medicines Agency agrees, new labels will indicate that the long-acting basal insulin Tresiba can be prescribed in tandem with a GLP-1 like Victoza, and that Victoza can be prescribed along with a long-acting basal insulin.

The potential expansion comes soon after the FDA put Tresiba at arm's-length in February, when it told the drugmaker to run cardiovascular safety tests before it would consider an approval.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.